Femasys Treasury Stock 2021-2025 | FEMY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Femasys treasury stock from 2021 to 2025. Treasury stock can be defined as common shares bought back by the issueing company and held in its treasury

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Femasys treasury stock from 2021 to 2025. Treasury stock can be defined as common shares bought back by the issueing company and held in its treasury

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$237.5B
Amgen (AMGN)	$162B
Gilead Sciences (GILD)	$142.8B
Vertex Pharmaceuticals (VRTX)	$120.5B
Bristol Myers Squibb (BMY)	$93.6B
CSL (CSLLY)	$84.5B
GSK (GSK)	$79.6B
Regeneron Pharmaceuticals (REGN)	$59.9B
Alnylam Pharmaceuticals (ALNY)	$44.3B
Argenex SE (ARGX)	$36.7B
BioNTech SE (BNTX)	$26.5B
Royalty Pharma (RPRX)	$20.9B
Insmed (INSM)	$20B
Biogen (BIIB)	$18.6B
Illumina (ILMN)	$16.9B
Incyte (INCY)	$15B
Genmab (GNMSF)	$14.7B
Genmab (GMAB)	$14.3B
Moderna (MRNA)	$12.4B
BioMarin Pharmaceutical (BMRN)	$11.3B
QIAGEN (QGEN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.2B
Exelixis (EXEL)	$9.9B
Bio-Techne Corp (TECH)	$9B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.8B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.7B
Legend Biotech (LEGN)	$7.4B